Arrowhead Research Corporation (ARWR)
Alvos Acquisition Conference Call
April 11, 2012 4:30 PM ET
ExecutivesBrooks Rahmer – IR Christopher Anzalone – CEO Analysts Todd Ulrich Ted Tenthoff – Piper Jaffray Presentation
Operator Good day and welcome to the Arrowhead Alvos Therapeutics Acquisition conference call and webcast. All participants will be in a listen-only mode. (Operator Instructions)
Previous Statements by ARWR
» Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript
» Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript
» Arrowhead Research Corp. F1Q10 (Qtr End 12/31/09) Earnings Call Transcript
» Arrowhead Research Corp. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
Thanks operator. Good afternoon everyone and thank you for joining us on the call today. With us – Brooks Rahmer?
Brooks Rahmer Hi, guys. Think I will say a few words. Thanks everybody for joining the call today. On the call with us are President and CEO Dr. Christopher Anzalone, COO Dr. Bruce Given, and CFO Ken Myszkowski. Management will provide a brief overview of the acquisition and will then open the call up to your questions. Before we begin, I would like to remind you that comments made during today's call may contain certain forward-looking statements within the meaning of Section 27(A) of the Securities Act of 1933 and Section 21(E) of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation those with respect to Arrowhead's goals, plans, and strategies are forward-looking statements. Without limiting the generality of the foregoing, words such as may, will, expect, believe, anticipate, intend, could, estimate, or continue, or the negative or other variations thereof, or comparable terminology, are intended to identify forward-looking statements.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts